and on study design, relevant outcomes, study population, source, type, amount, and duration of omega-3 fatty acid consumption, and parameters of methodological quality. A single cohort study has assessed the effects of omega-3 fatty acids on cognitive function with normal aging and found no association for fi sh or total omega-3 consumption. In four studies that assessed the effects of omega-3 fatty acids on incidence and treatment of dementia, a trend in favor of omega-3 fatty acids (fi sh and total omega-3 consumption) toward reducing risk of dementia and improving cognitive function was reported. The available data are insuffi cient to draw strong conclusions about the effects of omega-3 fatty acids on cognitive function in normal aging or on the incidence or treatment of dementia. However, limited evidence suggests a possible association between omega-3 fatty acids and reduced risk of dementia.
and on study design, relevant outcomes, study population, source, type, amount, and duration of omega-3 fatty acid consumption, and parameters of methodological quality. A single cohort study has assessed the effects of omega-3 fatty acids on cognitive function with normal aging and found no association for fi sh or total omega-3 consumption. In four studies that assessed the effects of omega-3 fatty acids on incidence and treatment of dementia, a trend in favor of omega-3 fatty acids (fi sh and total omega-3 consumption) toward reducing risk of dementia and improving cognitive function was reported. The available data are insuffi cient to draw strong conclusions about the effects of omega-3 fatty acids onthose older than 85 years old [1, 2] . Currently there are about four million people in the U.S. with AD, the most common type of dementia, and this number is expected to double by the year 2050 [2, 3] . There is increasing interest and focus on efforts aimed at identifying modifi able risk factors, including preventative dietary interventions. Various animal [4] [5] [6] and human studies [7, 8] have suggested a role for omega-3 fatty acids as a possible preventative strategy for dementia. However, these studies have reported mixed results. A number of dietary supplements with omega-3 fatty acids that claim to be neuroprotective have appeared on the market and several reports in the popular media claim that omega-3 fatty acid supplementation can prevent AD. Indeed, many Internet websites [e.g., 9, 10] promote and/or sell omega-3 fatty acids for dementia. Fish consumption is also increasingly recommended for older adults. However, mercury contamination of fi sh may be associated with worse performance on some cognitive tasks [11] . There is, therefore, an urgent need to determine whether suffi cient good quality evidence exists regarding the health benefi ts of omega-3 fatty acids as a dietary intervention for cognitive function in aging, and in dementia. However, to the best of our knowledge, the evidence for consuming omega-3 fatty acids as a modifiable risk factor for dementia has not yet been systematically synthesized. A systematic literature review was performed in order to determine whether suffi cient evidence exists to substantiate claims of a health benefi t for omega-3 fatty acids on cognitive function in normal aging and in dementia.
Methods
This study was part of a larger systematic review of the literature on the effects of intake of omega-3 fatty acids on neurological disorders [12] , and as a result, our initial search of the literature was broad. This report deals with the effects of omega-3 fatty acids on cognitive function in normal aging of older adults and on the incidence and treatment of dementia. SilverPlatter. Additional articles were identifi ed by scanning the references of relevant literature. The search terms used were broad and focused on identifying any relevant article dealing with the conditions of interest in human subjects. Our search was not restricted by language of publication or study design in order to increase specifi city. Two of the investigators (W.A.M. and A.M.I.) who were blinded to author and source information (i.e. journal and institution) independently reviewed titles and abstracts. The full text of any articles that were fl agged as relevant by either of the two reviewers was obtained for further review. Our objective at this initial stage of screening was to identify articles that described studies about the effects of omega-3 fatty acids on cognitive function with normal healthy aging or on dementia in human subjects. The full text of any articles for which it was not possible to determine relevance from the title and/or abstract was also retrieved for further review. At this stage, only titles and/or abstracts that clearly did not meet these criteria for inclusion were rejected.
Study Identifi cation

Study Selection
Any retrieved articles were independently reviewed by the two investigators (W.A.M. and A.M.I.) using a structured screening form in order to determine whether they should be accepted for further review. Reviewers were not blinded to journal or authors at this stage. The following inclusion criteria were used to select studies for further detailed review: (1) the study reported research on human subjects; (2) the study design was any of the following: controlled clinical trials (randomized or nonrandomized), prospective cohort studies, case-control studies, and case series; (3) studies had to describe a difference in omega-3 fatty acid content between study arms (case series were excluded from this criterion), and (4) studies had to describe the effect of omega-3 fatty acids on any of the following outcomes: cognitive function with normal aging, incidence of dementia or treatment of dementia. Cross-sectional studies and case reports were excluded. The reviewers resolved any disagreements by consensus. Articles were not masked.
Data Extraction and Analysis
Two of the investigators (W.A.M. and A.M.I.) independently abstracted detailed data onto a structured specialized quality review form (QRF) from all the studies that met our screening criteria. Any differences were resolved by consensus. Several outside scientists were consulted to complete QRFs for foreign language articles.
Data were collected from each article for study design, the outcomes of interest, study sample characteristics, details on the intervention, such as the dose, frequency, and duration, the elapsed time between the intervention and outcome measurements, and the type of outcome measures ( tables 1 and 2 ).
Information about the methodological quality of the studies was also abstracted. To evaluate the quality and execution of clinical trials, data were also collected about the randomization, blinding, withdrawals and dropouts, and concealment of allocation. Jadad scores were used to assess the quality of the randomized controlled trials [13] . For observational studies, data were collected about the validity of ascertainment of cases and exposure, description of withdrawals and dropouts, and adjustment for confounders and blinded assessment of exposure and case status when ascertaining case and exposure status, respectively [14, 15] . Data about the methodologic quality of the cohort studies are presented in table 1 and data regarding the quality of the randomized clinical trial (RCT) are presented in table 2 .
Data Analysis
Because of the heterogeneity among studies, too few studies met the inclusion criteria, and as a result, it was not possible to perform a meta-analysis (pooled statistical analyses). The overall effect of omega-3 fatty acids across the studies and the unit of analysis for omega-3 fatty acid consumption, i.e. fi sh, total omega-3 fatty acids, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), or alpha linolenic acid (ALA) are described. The point estimates and statistical testing that were described in the original studies are summarized.
Results
The initial broad search of the literature on the effects of omega-3 fatty acids on neurological disorders yielded 5,865 citations. Two of the investigators (W.A.M. and A.M.I.) identifi ed 497 of these article titles and abstracts to be relevant to the questions related to the effects of omega-3 fatty acids on neurological disorders. However, most of these did not specifi cally deal with cognitive function in aging or dementia. Forty-nine studies were identifi ed that deal with the effects of omega-3 fatty acids on cognitive function in normal aging or dementia, and that passed the preliminary screening criteria. These studies were further reviewed using the QRF. We further excluded studies from our fi nal analysis set based on study design and whether the study assessed the difference in omega-3 content across study arms. Among the 49 studies reviewed with the QRF, 44 studies were rejected because they did not meet our study design criteria or did not distinguish between omega-3 fatty acid content between the study arms. Results from this initial literature search are detailed in fi gure 1 .
In total, fi ve studies were identifi ed that described the effects of omega-3 fatty acids on cognitive function with aging or dementia; one was an RCT and four were cohort studies. The characteristics of the studies that were analyzed are described in table 3 .
Effects of Omega-3 Fatty Acid Intake on Cognitive Function in Normal Aging
A single prospective cohort study [16] that evaluated the effects of omega-3 fatty acids on cognitive function in normal aging was identifi ed. This study investigated the association between omega-3 fatty acids and cognitive function in an original cohort of 939 communitydwelling men living in the Dutch town of Zutphen, who were participants in the Zutphen Elderly Study, a longitudinal study on risk factors for various chronic diseases. Data about dietary intake were collected by trained interviewers in 1985 and 1993, and data about cognitive function were collected in 1990 and 1993. Complete dietary information was collected on 476 men, and complete information regarding cognitive function was collected on 342 men. The relationship between both fi sh consumption and total omega-3-fatty acid consumption with both cognitive impairment and cognitive decline was assessed. Cognitive impairment was defi ned as a Mini-Mental State Examination (MMSE) score of ^ 25. Cognitive decline was defi ned as a drop of more than two points in the MMSE over a 3-year period, which corresponds to the 15th percentile of change. Compared with no fi sh consumption, fi sh consumption was inversely associated with cognitive impairment in crude analyses, but not after adjustment for multiple variables ( table 4 ). Fish consumption was also inversely associated with development of cognitive decline, though not signifi cantly so ( table 4 ) . Total omega-3 fatty acid consumption was not related to cognitive impairment or cognitive decline. A dose effect was observed for omega-3 fatty acid consumption and cognitive impairment on unadjusted analyses (p for trend = 0.9), but not on adjusted analyses. No dose effect was found with omega-3 fatty acid consumption and cognitive decline.
This study adjusted for confounders, used valid methods to determine exposure and outcomes, ascertained that exposure occurred before outcome measurement, and described withdrawals and dropouts.
Effects of Omega-3 Fatty Acid Intake on the Incidence of Dementia
Three prospective cohort studies [17] [18] [19] that evaluated the effect of omega-3 fatty acids on the incidence of dementia were identifi ed ( table 4 ). All three of the studies assessed the incidence of dementia relative to fi sh consumption; one also assessed risk relative to total omega-3 fatty acid consumption, and relative to ALA, EPA, and DHA consumption, respectively [18] . Fish consumption Table 4 . Estimates of effect of omega-3 fatty acids on cognitive function and dementia in cohort studies by category of omega-3 consumption was associated with a signifi cant reduction in the incidence of non-Alzheimer dementia in two studies [17, 19] , although in one statistical signifi cance was lost with multivariable adjustment [17] ( table 4 ) . Fish consumption was associated with a reduced risk of Alzheimer's dementia in all three of the studies; the association was statistically signifi cant in one [19] and nearly so in the other two [17, 18] ( table 4 ) . Total omega-3 fatty acid consumption and consumption of DHA were associated with a significant reduction in the incidence of AD; consumption of ALA and EPA were not [18] ( table 4 ) . Dose effects were observed for fi sh in one study [19] and for total omega-3 consumption and DHA in another [18] (p for trend ! 0.05 for each; table 4 ). One study assessed whether gender modifi ed the effect of total omega-3 fatty acid consumption or consumption of fi sh, ALA, EPA, or DHA [18] . Total intake of omega-3 fatty acids was protective in females only (p for interaction = 0.02); gender did not modify the effect of fi sh, ALA, EPA, or DHA.
Two of the studies [18, 19] assessed the infl uence of covariates on the effect of omega-3 fatty acids on incidence of dementia. In one study [18] , the multivariable relative risks for intakes of total omega-3 fatty acids, DHA, and EPA did not change when adjusted for vitamin E intake, other fat intake and cardiovascular disease. In the same study, multivariable risks for intake of ALA were reported as approximately 1.0 with adjustment for vitamin E but not affected by adjustment for cardiovascular disease; intake of ALA was strongly protective among people with the apolipoprotein E4 genotype (RR = 0.08 per natural log of increase (in milligram) in ALA, p = 0.02). In the other study [19] , estimates of relative risk did not change with adjustment for cigarette smoking, alcohol consumption, fi ber consumption, antioxidant intake, stroke, myocardial infarction, or serum total and high-density lipoprotein cholesterol.
Among these three studies, all adjusted for confounders, reported using valid methods to ascertain outcomes, and confi rmed that the exposure occurred prior to the outcome.
Effects of Omega-3 Fatty Acid Intake on the Treatment of Dementia
One study [20] was identifi ed that assessed omega-3 fatty acids as treatment for dementia. This RCT assessed the effect of supplementation with DHA on cognitive function among 20 elderly nursing home residents with vascular dementia. Cognitive functioning was evaluated using Hasegawa's Dementia Rating Scale (HDS-R) and MMSE scores at baseline, after 3, 6, and 12 months. Baseline HDS-R and MMSE scores were 15-22, consistent with mild to moderate dementia. HDS-R and MMSE scores improved in the DHA-treated group but not among patients who were not treated with DHA ( table 5 ). Comparisons between groups were signifi cant at 3 and 6 months for the HDS-R and at 6 months for the MMSE.
To assess the quality of this study, a summary quality score (A, B, or C) was applied based on the combination of the Jadad [13] instrument and reporting of concealment of allocation to this single RCT. Although this trial is described as randomized, the randomization procedure is not described as double blind, and there is no description regarding blinding, withdrawals or dropouts. This study, therefore, scored a summary quality score of C (Jadad score = 1; concealment of allocation was not reported; table 2 ) and can be considered of poor quality. 
Discussion
Although the lay press and commercial advertisements have purported that omega-3 fatty acids are benefi cial for cognitive function and the treatment of dementia, we were unable to fi nd strong evidence to support these claims. A detailed systematic search of the literature identifi ed only fi ve articles that informed these topics. The data in these studies are insuffi cient to draw conclusions about the effects of omega-3 fatty acids on cognitive function in normal aging or on the treatment of dementia. However, they do suggest a possible association between omega-3 fatty acids and reduced risk of dementia, but this fi nding must be confi rmed in other studies before strong conclusions can be drawn.
Although there are too few studies to draw fi rm conclusions about the effects of omega-3 fatty acids on the incidence, the fact that each of the three prospective cohort studies [17] [18] [19] demonstrated that fi sh consumption was associated with a reduced risk of Alzheimer's dementia, makes it less likely that these fi ndings are spurious. Furthermore, these fi ndings are consistent with animal models and some pathophysiological theories of dementia. Work in animal models has reported superior learning and memory in animals fed omega-3 fatty acids compared with control animals [4, 5] . In a transgenic mouse model, dietary DHA improved memory, increased synapse density and decreased A ␤ toxicity, thus providing evidence of protection against AD and cognitive decline [6] .
It is important to point out that a major limitation of studies of omega-3 fatty acids and disease is the lack of standardized methods to measure nutrient levels [21] . Thus, it is possible to report overestimation or underestimation of true associations with outcomes due to errors in measurement of nutrients. Because baseline dietary consumption of omega-3 and omega-6 fatty acids may infl uence the effects of supplementation with omega-3 fatty acids, trials of omega-3 fatty acids should include a baseline assessment of dietary omega-3 and omega-6 fatty acid intake; however, again, few of the studies that we identifi ed did so. Thus, we could not determine true total intakes of omega-3 fatty acids. Furthermore, the studies we reviewed lacked a uniform or consistent approach to quantifying the type of omega-3 fatty acid. For example, some measured nutrient intake from food frequency questionnaires without reporting type of fi sh or method of preparation; other studies defi ned omega-3 fatty acid supplements. This issue will increasingly become important in the design of future studies of omega-3 fatty acids and disease.
It is also important to note that in observational studies, it is not possible to control exposure [22] , which can lead to confounding [23] . Observational studies focused on repeated measures of diet for long-term intake, and subgroup analysis among persons with cardiovascular conditions (including history of stroke or myocardial infarction) also need to be performed in order to determine whether change in diet among these subgroups results in confounding due to change in dietary intake.
The paucity of evidence in this area suggests that further epidemiological and clinical research remains to be done before conclusions can be drawn or policy recommendations can be made regarding the health effects of omega-3 fatty acids on cognition or prevention of dementia. Because our search methods were comprehensive, this apparent lack of published literature likely represents an actual paucity of research on this topic.
